NIMG-03. IMPACT OF CONCURRENT IMMUNOTHERAPY AND STEREOTACTIC RADIOSURGERY ON METASTATIC BRAIN DISEASE: A THREE-DIMENSIONAL MAGNETIC RESONANCE FINGERPRINTING RADIOMIC ANALYSIS

Abstract

Abstract BACKGROUND Unlike traditional chemotherapy (limited by the blood-brain barrier), the central nervous system penetrance of immunotherapy allows for synergy with stereotactic radiosurgery (SRS), the standard-of-care management of limited brain metastases. Magnetic resonance fingerprinting (MRF) is a novel technology allowing for simultaneous imaging quantification of multiple tissue properties. We present the first serial MRF results in concomitant SRS/immunotherapy for metastatic brain disease. METHODS A patient with known history of small cell lung cancer (SCLC) presented with a seizure. MRI revealed a solitary 1 cm right occipital metastasis, subsequently receiving SRS rather than whole-brain radiation therapy to optimize cognition preservation. Durvalumab (with carboplatin/etoposide) was given one week before SRS (22 Gy single-fraction). Pre-SRS MRF scans were obtained with the Gamma Knife stereotactic headframe in place. Post-SRS MRF scans were obtained at 1, 3, and 5 months. MRF data was processed and region of interest analysis was performed to measure T1 and T2 values within the lesion using MATLAB. RESULTS The mean T1 and T2 values of the solid tumor (ST) in precontrast MRF maps decreased over time with a slight increase at final follow-up. Specifically, the T1 values decreased from 2131 ms (Pre-SRS) to 1018 ms, then 996 ms followed by a slight increase to 1296 ms. Similarly, the T2 values progressively decreased from 143 ms (Pre-SRS) to 45 ms (first follow-up) to 43 ms (3-month follow-up), with an increase (51 ms) at last follow-up. CONCLUSIONS In this first report of MRF in concomitant immunotherapy/Gamma Knife SRS (and the first in a SCLC patient). MRF demonstrated serial drop in T1 and T2 over time followed by slight increase at 5 months follow-up. The alterations observed in T1 and T2 MRF are compatible with post-treatment effects in the tumor's tissue characteristics, including decreased cellularity, water content, and presence of paramagnetic substances.